Reuters logo
BRIEF-Tyme reports encouraging efficacy and safety data from first human study of sm-88
November 6, 2017 / 1:47 PM / 13 days ago

BRIEF-Tyme reports encouraging efficacy and safety data from first human study of sm-88

Nov 6 (Reuters) - Tyme Technologies Inc:

* Tyme announces encouraging efficacy and safety data from first human study of sm-88 in women with metastatic breast cancer

* Tyme Technologies Inc - ‍no drug-related serious adverse events were observed during sm-88 therapy​

* Tyme Technologies Inc - ‍43 percent of patients demonstrated complete or partial responses while on monotherapy during study of sm-88​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below